

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6504741

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
CORVIDIA THERAPEUTICS, INC.		10/29/2020
RECEIVING PARTY DATA		
Name:	NOVO NORDISK A/S	
Street Address:	NOVO ALLE	
City:	BAGSVÆRD	
State/Country:	DENMARK	
Postal Code:	2880	
PROPERTY NUMBERS Total: 15		
Property Type	Number	
Application Number:	16482038	
Application Number:	62453257	
Application Number:	62448358	
Application Number:	62476535	
Application Number:	16479183	
Application Number:	62476531	
Application Number:	16240670	
Application Number:	16396378	
Application Number:	62614134	
PCT Number:	US1912430	
Application Number:	62700751	
Application Number:	62876923	
Application Number:	62841662	
Application Number:	62983459	
Application Number:	62983466	
CORRESPONDENCE DATA		
Fax Number:	(650)938-5200	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6469408058	

Email:	kwoo@fenwick.com
Correspondent Name:	BRYTE V. GORDON
Address Line 1:	FENWICK & WEST LLP
Address Line 2:	801 CALIFORNIA STREET
Address Line 4:	MOUNTAIN VIEW, CALIFORNIA 94041

ATTORNEY DOCKET NUMBER:	32601-01000
--------------------------------	-------------

NAME OF SUBMITTER:	BRYTE V. GORDON, REG. NO. 63,660
---------------------------	----------------------------------

SIGNATURE:	/Bryte V. Gordon/
-------------------	-------------------

DATE SIGNED:	01/20/2021
---------------------	------------

Total Attachments: 7

source=Corvidia Novo Nordisk IP Assignment#page1.tif

source=Corvidia Novo Nordisk IP Assignment#page2.tif

source=Corvidia Novo Nordisk IP Assignment#page3.tif

source=Corvidia Novo Nordisk IP Assignment#page4.tif

source=Corvidia Novo Nordisk IP Assignment#page5.tif

source=Corvidia Novo Nordisk IP Assignment#page6.tif

source=Corvidia Novo Nordisk IP Assignment#page7.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (this "**Assignment**"), dated as of 29 October 2020 ("**Effective Date**"), is entered into between Corvidia Therapeutics, Inc., a Delaware corporation ("**Assignor**") and Novo Nordisk A/S, an entity organized under the laws of Denmark ("**Assignee**") (each referred to as a "**Party**" and together the "**Parties**").

WITNESSETH

WHEREAS, pursuant to that certain Asset Purchase Agreement, between Assignor and Assignee, dated as of 29 October 2020 (the "**Purchase Agreement**"), Assignor has agreed to deliver to Assignee this Assignment with respect to the Assigned IP (as defined herein); and

WHEREAS, pursuant to this Assignment, Assignor desires to assign to Assignee all of the Assigned IP.

NOW, THEREFORE, for good and valuable consideration (including pursuant to the Purchase Agreement), the receipt and adequacy of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree as follows.

1. For the purposes of this Assignment, the term "**Intellectual Property**" means all of the following in any jurisdiction throughout the world: (i) any and all *patents* and/or patent applications and provisional applications, all inventions disclosed therein, and any and all continuations, continuations-in-part, continued prosecution applications, divisions, renewals, patents of addition, reissues, confirmations, registrations, revalidations, revisions and re-examinations thereof, utility models, petty patents, design registrations and any and all patents issuing therefrom and any and all foreign counterparts thereof and extensions of any of the foregoing; (ii) *copyrights* and works of authorship and registrations and applications therefor for any designs; (iii) *know-how*, whether or not patentable, inventions, discoveries, data, information, protocols, processes, methods, techniques, materials, technology, results, algorithms, marketing reports and plans, market research, expertise, or other know-how; (iv) *trade secrets* and other confidential information relating to the foregoing; and (v) all *other intellectual property rights* in the foregoing.
2. Assignor hereby irrevocably assigns, transfers and conveys to Assignee all of Assignor's right, title and interest in, and to and under any and all Intellectual Property owned by Assignor, including but not limited to those patents listed in Schedule A hereto (collectively the "**Assigned IP**"), in the United States and elsewhere and together with all (i) income, royalties, claims for damages, profits and costs and damages and payments due or payable at the Effective Date or thereafter (including damages and payments for any past, current or future infringements or misappropriations of the Assigned IP); (ii) choses in action and rights to sue, recover and collect for any past, present or future infringements or misappropriations of the Assigned IP, and (iii) corresponding rights that, now or hereafter, may be secured throughout the world with respect to the Assigned IP.
3. From and after the Effective Date, in the event any further action is necessary to carry out

the purposes of this Assignment, Assignor and its directors, officers, managers and members shall take all such necessary action as may be reasonably requested by Assignee to achieve such intent, including the execution of any documentation reasonably requested by Assignee to effectuate the assignment, transfer and conveyance of the Assigned IP (including any documentation for filing with the United States Patent and Trademark Office or any equivalent foreign agency).

4. Assignor hereby authorizes and requests the Commissioner of Patents and any equivalent authority, entity or agency or registrar to record Assignee as the assignee and owner of the Assigned IP.
5. This Assignment and all disputes or controversies arising out of or relating to this Assignment shall be governed by, and construed in accordance with, the laws of Denmark, without reference to its choice of laws rules. Each Party hereby irrevocably consents to the exclusive jurisdiction of and venue in the courts of Denmark with respect to any claim, action or proceeding arising out of or in connection with this Agreement or the transactions contemplated hereby.
6. This Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.


[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Parties hereto have caused this Assignment to be executed as of the date first written above by their respective officers thereunto duly authorized.


CORVIDIA THERAPEUTICS INC.

By _____
Name: _____
Title: _____


NOVO NORDISK A/S

DocuSigned by:

CARTER OF NATA

By _____
Name: Karsten Munk Knudsen
Title: Executive Vice President


DocuSigned by:

CARTER OF NATA

By _____
Name: Mads Krogsgaard Thomsen
Title: Executive Vice President



IN WITNESS WHEREOF, the Parties hereto have caused this Assignment to be executed
as of the date first written above by their respective officers thereunto duly authorized.

CORVIDIA THERAPEUTICS INC.

By  DocuSigned by:
Name: Ulrich Christian Otte
Title: Director and President

NOVO NORDISK A/S

By _____
Name: Karsten Munk Knudsen
Title: Executive Vice President

By _____
Name: Mads Krogsgaard Thomsen
Title: Executive Vice President

SCHEDULE A
PATENTS

(see attached)

Intellectual Property Assignment Agreement				
Schedule A				
Patent filings with Corvidia Therapeutics as application / co-applicant				
COUNTRY	TITLE (preceded by Corvidia reference number)	STATUS	APPLICATION NUMBER	FILING DATE
AU	(008AU) Treatment of Diuretic Resistance	Pending	2018214554	feb 1, 2018
CA	(008CA) Treatment of Diuretic Resistance	Pending	3051865	feb 1, 2018
CN	(008CN) Treatment of Diuretic Resistance	Pending	201880020541.7	feb 1, 2018
EP	(008EP) Treatment of Diuretic Resistance	Pending	18747692.4	feb 1, 2018
HK	(008HK) Treatment of Diuretic Resistance	Pending	62020008914.7	feb 1, 2018
IL	(008IL) Treatment of Diuretic Resistance	Pending	268294	feb 1, 2018
IN	(008IN) Treatment of Diuretic Resistance	Pending	201917034989	feb 1, 2018
JP	(008JP) Treatment of Diuretic Resistance	Pending	2019-541430	feb 1, 2018
KR	(008KR) Treatment of Diuretic Resistance	Pending	10-2019-7025663	feb 1, 2018
MX	(008MX) Treatment of Diuretic Resistance	Pending	MX/a/2019/008966	feb 1, 2018
SG	(008SG) Treatment of Diuretic Resistance	Pending	11201906852X	feb 1, 2018
SG	(008SGD1) Treatment of Diuretic Resistance	Pending	102019121285	feb 1, 2018
TW	(008TW) Precision Treatment of Heart Failure and Cardiorenal Syndrome	Allowed	107103707	feb 1, 2018
US	(008US) Treatment of Diuretic Resistance	Pending	16/482,038	feb 1, 2018
US	(008US) Treatment of Diuretic Resistance	Pending	16/482,038	feb 1, 2018
US	(008USP1) Precision Treatment of Heart Failure and Cardiorenal Syndrome	Expired	62/453,257	feb 1, 2017
WO	(008WO) Treatment of Diuretic Resistance	Completed	PCI/US2018/016508	feb 1, 2018
US	(009USP1) Methods of Treating Hypertriglyceridemia with ApoC-II Mimetic Peptides	Expired	62/448,358	jan 19, 2017
US	(009USP2) Methods of Treating Hypertriglyceridemia with ApoC-II Mimetic Peptides	Expired	62/476,535	mar 24, 2017
AU	(010AU) ApoC-II Mimetic Peptides	Pending	2018210404	jan 19, 2018
BR	(010BR) ApoC-II Mimetic Peptides	Pending	BR 11 2019 014707 1	jan 19, 2018
CA	(010CA) ApoC-II Mimetic Peptides	Pending	3,050,106	jan 19, 2018
CN	(010CN) ApoC-II Mimetic Peptides	Pending	201880019604.7	jan 19, 2018
EA	(010EA) ApoC-II Mimetic Peptides	Pending	201991491	jan 19, 2018
EP	(010EP) ApoC-II Mimetic Peptides	Pending	18742118.5	jan 19, 2018
HK	(010HK) ApoC-II Mimetic Peptides	Pending	62020008181.3	jan 19, 2018
IL	(010IL) ApoC-II Mimetic Peptides	Pending	268093	jan 19, 2018
IN	(010IN) ApoC-II Mimetic Peptides	Pending	201917032726	jan 19, 2018
JP	(010JP) ApoC-II Mimetic Peptides	Pending	2019-539809	jan 19, 2018
KR	(010KR) ApoC-II Mimetic Peptides	Pending	10-2019-7024024	jan 19, 2018
MX	(010MX) ApoC-II Mimetic Peptides	Pending	MX/a/2019/008529	jan 19, 2018
NZ	(010NZ) ApoC-II Mimetic Peptides	Pending	755599	jan 19, 2018
WO	(010PCT) ApoC-II Mimetic Peptides	Completed	PCI/US2018/014532	jan 19, 2018
SG	(010SG) ApoC-II Mimetic Peptides	Pending	11201906422V	jan 19, 2018
SG	(010SGD1) ApoC-II Mimetic Peptides	Pending	10201911974U	jan 19, 2018
TW	(010TW) ApoC-II Mimetic Peptides	Pending	107102123	jan 19, 2018
US	(010US) ApoC-II Mimetic Peptides	Pending	16/479,183	jan 19, 2018
US	(010USP1) ApoC-II Mimetic Peptides	Expired	62/476,531	mar 24, 2017
ZA	(010ZA) ApoC-II Mimetic Peptides	Pending	2019/04733	jan 19, 2018
AE	(013AE) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	P6001003/2020	jan 4, 2019
AU	(013AU) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	2019205936	jan 4, 2019
BR	(013BR) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	BR112020013519 4	jan 4, 2019
CA	(013CA) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	3,087,699	jan 4, 2019
CL	(013CL) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	202001790	jan 4, 2019
CN	(013CN) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	201980014573.0	jan 4, 2019
CO	(013CO) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	NC2020/0009519	jan 4, 2019
DZ	(013DZ) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	200382	jan 4, 2019
EA	(013EA) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	202091640	jan 4, 2019
EG	(013EG) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	PCT 952/2020	jan 4, 2019
EP	(013EP) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	19735844.3	jan 4, 2019
ID	(013ID) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	P00202005595	jan 4, 2019
IL	(013IL) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	275696	jan 4, 2019
IN	(013IN) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	202017031759	jan 4, 2019
IR	(013IR) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	139950140003003095	jan 4, 2019
JP	(013JP) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	2020-536963	jan 4, 2019
KR	(013KR) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	10-2020-7021357	jan 4, 2019
KW	(013KW) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	KW/P/2020/246	jan 4, 2019
MX	(013MX) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	MX/a/2020/006882	jan 4, 2019
MY	(013MY) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	PI20200003508	jan 4, 2019
NZ	(013NZ) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	765860	jan 4, 2019
PE	(013PE) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	914-2020	jan 4, 2019
PH	(013PH) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	1-2020-551040	jan 4, 2019
QA	(013QA) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	QA/202007/000364	jan 4, 2019
RU	(013RU) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	2020125805	jan 4, 2019
SA	(013SA) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	520412386	jan 4, 2019
SG	(013SG) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	11202006157V	jan 4, 2019
TH	(013TH) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	2001003835	jan 4, 2019
US	(013US) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Abandoned	16/240,670	jan 4, 2019
US	(013USC1) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	16/396,378	apr 26, 2019
US	(013USP1) Methods for Treating IL-6 Mediated Inflammation	Expired	62/614,134	jan 5, 2018
VN	(013VN) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	1-2020-04470	jan 4, 2019
WO	(013WO) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Completed	PCI/US2019/012430	jan 4, 2019
ZA	(013ZA) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	2020/04074	jan 4, 2019
US	(014US) Methods of Treating Diabetes with ApoC-II Mimetic Peptides	Unfiled		
US	(014USP1) Methods of Treating Diabetes with ApoC-II Mimetic Peptides	Unfiled		
US	(016US) ApoE-ApoC2 Mimetic Peptides	Unfiled		
US	(016USP1) ApoE-ApoC2 Chimeric Peptides	Abandoned	62/700,751	jul 19, 2018
US	(016USP2) ApoE-ApoC2 Chimeric Peptides	Abandoned	62/876,923	jul 22, 2019
EP	(017EPP1) Anti-IL-6 Antibody Formulation	Abandoned	19181345.0	jun 19, 2019
US	(017USP1) Anti-IL-6 Antibody Formulation	Expired	62/841,662	maj 1, 2019

WO	(017WO) Anti-IL-6 Antibody Formulation	Pending	PCT/US2020/030865	apr 30, 2020
US	(018US) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Unfiled		
US	(018USP1) Methods for Treating IL-6 Mediated Inflammation Without Immunosuppression	Pending	63/050,441	jul 10, 2020
US	(019US) IL-11 Antibody	Unfiled		
US	(019USP1) Anti-IL-11 Antibodies	Pending	62/983,459	feb 28, 2020
US	(020US) Anti-IL-11 Receptor Antibodies	Unfiled		
US	(020USP1) Anti-IL-11RA Antibodies	Pending	62/983,466	feb 28, 2020
US	(021US) IL-11 Bispecific Antibody	Unfiled		
US	(021USP1) IL-11 Bispecific Antibody	Unfiled		
US	(022US) Treatment of Cytokine Release Syndromes	Unfiled		
US	(022USP1) Treatment of Cytokine Release Syndromes	Pending	63/004,374	apr 2, 2020
US	(022USP2) Treatment of Cytokine Release Syndromes	Pending	63/012,570	apr 20, 2020